Phase 3 N=214 Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
Partial Epilepsy
Primary: Percent Change in Seizure Rate — -26.3 percentage of change in seizure rate
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=36 Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA
Dyskeratosis Congenita · Aplastic Anemia
Primary: Neutrophil Engraftment — 15; 20 Participants
Phase 3 N=10 Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.
Retinal Vein Occlusion · Macular Edema
Primary: Macular Function Using Microperimetry — 2.7; 12.7; 4.2; 10.7 dB
Phase 3 N=44 Effectiveness of Multicomponent Lipid Emulsion in Preterm Infants Requiring Parenteral Nutrition
Cholestasis
Primary: Incidence of Neonatal Cholestasis — 1; 2 Participants
Phase 3 N=1,246 Long Term Safety of Naldemedine
Opioid-induced Constipation
Primary: Number of Participants With Adverse Events — 425; 446; 149; 121 participants
Phase 3 N=709 Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients
Kidney Transplantation
Primary: Estimated Glomerular Filtration Rate (eGFR) — 64.1; 61.5; 58.4 mL/min/1.73m^2
Phase 3 N=166 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma · Stage III Childhood Hodgkin Lymphoma · Stage IV Childhood Hodgkin Lymphoma
Primary: Second-event-free Survival — 0.91 Probability of survival
Phase 3 N=553 Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation
Opioid-induced Constipation
Primary: Percentage of Participants With a Spontaneous Bowel Movement (SBM) Response — 52.5; 33.6 percentage of participants — p=<0.0001
Phase 3 N=329 BIOHELIX-I Bare Metal Stent Study
Coronary Arteries Disease
Primary: Target Vessel Failure Rate — 9.06; 0.95; 1.58; 7.26 Percentage of participants
Phase 3 N=20 Azelaic Acid on Demodex Counts in Rosacea
Rosacea
Primary: Demodex Count — 40; 18 number of demodex
Phase 3 N=100 Combined Medication for Improved Analgesia in Superficial Pain
Pain
Primary: Pain Scores on Standardized Experimental Pain Testing — 59.6; 54.0; 44.1; 45.3 units on a scale
Phase 3 N=769 Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
Cancer · Cataract · Low Bone Mineral Density
Primary: Percentage of Participants With Lens Opacification Event Development or Progression by Month 12 — 33.2; 33.5 percentage of participants — p=0.0026
Phase 3 N=547 Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation
Opioid-induced Constipation
Primary: Percentage of Participants With a Spontaneous Bowel Movement (SBM) Response — 47.6; 34.6 percentage of participants — p=0.0020
Phase 3 N=204 Combined Behavioral and Drug Treatment of Overactive Bladder in Men
Overactive Bladder · Lower Urinary Tract Symptoms
Primary: Change in Frequency of Urination After 6-week Intervention (Last Observation Carried Forward) — 2.7; 1.5; 3.3 voids per day — p=<.0001
Phase 3 N=764 Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women
Vulvovaginal Atrophy · Menopause · Dyspareunia
Primary: Co-Primary Efficacy Endpoint - Vaginal Superficial Cells — 17.50; 16.72; 23.20; 5.63 percentage of vaginal superficial cells — p=< 0.0001